Low Rates of Poliovirus Antibodies in Primary Immunodeficiency Patients on Regular Intravenous Immunoglobulin Treatment
Poliovirus has been nearly eliminated as part of a world-wide effort to immunize and contain circulating wild-type polio. Nevertheless, poliovirus has been detected in water supplies and represents a threat to patients with humoral immunodeficiencies where infection can be fatal. To define the risk, we analyzed antibodies to poliovirus 1, 2, and 3 in serum samples collected over a year from patients with primary immunodeficiency diseases (PID) on regular intravenous immunoglobulin (IVIG) replacement.
Twenty-one patients on regular IVIG replacement therapy were evaluated: Twelve patients with common variable immune deficiency (CVID), six with X-linked agammaglobulinemia (XLA), and three with hyper IgM syndrome (HIGM). Over 1 year, four blood samples were collected from each of these patients immediately before immunoglobulin infusion. One sample of IVIG administered to each patient in the month before blood collection was also evaluated. Poliovirus antibodies were quantified by seroneutralization assay.
All IVIG samples had detectable antibodies to the three poliovirus serotypes. Despite that, only 52.4, 61.9, and 19.0% of patients showed protective antibody titers for poliovirus 1, 2, and 3, respectively. Only two patients (9.5%) had protective antibodies for the three poliovirus serotypes on all samples. Most patients were therefore susceptible to all three poliovirus serotypes.
This study demonstrates the need for ongoing vigilance regarding exposure of patients with PID to poliovirus in the community.
KeywordsPrimary immunodeficiency diseases poliovirus antibodies intravenous immunoglobulin Global Polio Eradication Initiative antibody deficiency common variable immunodeficiency X-linked agammaglobulinemia Hyper IgM syndrome
This study was funded by the FAPESP (2011/06136-6), a Brazilian Funding Agency.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 1.Polio Global Eradication Initiative, 2018.http://polioeradication.org/polio-today/polio-now/
- 19.Nobre FA, Gonzalez IG, Simao RM, de Moraes Pinto MI, Costa-Carvalho BT. Antibody levels to tetanus, diphtheria, measles and varicella in patients with primary immunodeficiency undergoing intravenous immunoglobulin therapy: a prospective study. BMC Immunol. 2014;15:26.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Simao-Gurge RM, Costa-Carvalho BT, Nobre FA, Gonzalez IG, de Moraes-Pinto MI. Prospective evaluation of Streptococcus pneumoniae serum antibodies in patients with primary immunodeficiency on regular intravenous immunoglobulin treatment. Allergol Immunopathol (Madr). 2017;45:55–62.CrossRefGoogle Scholar
- 27.Orange JS, Du W, Falsey AR. Therapeutic immunoglobulin selected for high antibody titer to RSV also contains high antibody titers to other respiratory viruses. Front Immunol. 2015;6(431)Google Scholar
- 33.Centers for Disease C, and Prevention. Outbreaks following wild poliovirus importations—Europe, Africa, and Asia, January 2009–September 2010. MMWR Morb Mortal Wkly Rep. 2010;59:1393–9.Google Scholar
- 36.Centers for Disease C, and Prevention. Update on vaccine-derived polioviruses—worldwide, July 2009–March 2011. MMWR Morb Mortal Wkly Rep. 2011;60:846–50.Google Scholar
- 39.Halsey NA, Pinto J, Espinosa-Rosales F, Faure-Fontenla MA, da Silva E, Khan AJ, et al. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull World Health Organ. 2004;82:3–8.PubMedPubMedCentralGoogle Scholar
- 41.Aghamohammadi A, Abolhassani H, Kutukculer N, Wassilak SG, Pallansch MA, Kluglein S, et al. Patients with primary immunodeficiencies are a reservoir of poliovirus and a risk to polio eradication. Front Immunol. 2017;8(685)Google Scholar
- 42.Domingues CM, de Fatima Pereira S, Cunha Marreiros AC, Menezes N, Flannery B. Introduction of sequential inactivated polio vaccine-oral polio vaccine schedule for routine infant immunization in Brazil’s National Immunization Program. J Infect Dis. 2014;210(Suppl 1):S143–51.CrossRefPubMedPubMedCentralGoogle Scholar